Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Zelensky sees win for Ukraine as EU finally reaches funding deal - 2Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- 3Fundamental Home Exercise center Hardware: Amplify Your Exercises
- 4UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- 5Moscow accuses Berlin of stifling the opposition
- Find the Mysteries of Powerful Using time productively: Augmenting Efficiency and Proficiency
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Instructions to Plan for Your Teeth Substitution Methodology
- 5 Pizza Fixings That Characterize Your Character
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Parents who delay baby's first vaccines also likely to skip measles shots
- Nature's Best: A Manual for Beautiful Train Rides
- Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- 2025 Yachting Editors' Choice Awards: Yachts
